GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Valuation Rank

Imunon (FRA:CBO) Valuation Rank


View and export this data going back to 2012. Start your Free Trial

What is Imunon Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Imunon Valuation Rank Related Terms

Thank you for viewing the detailed overview of Imunon's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Valuation Rank
Comparable Companies
INAB CING ZEOX PRTG MEIP BOLT CLRB ELEV SLGL NRXS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IMNN:USA
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Website
https://www.imunon.com
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).